Side-by-side comparison of AI visibility scores, market position, and capabilities
Mental health marketplace connecting patients with in-network therapists and psychiatrists, Los Angeles CA, raised $65M+. Insurance-covered access in all 50 states.
Rula is a Los Angeles, California-based mental health marketplace founded in 2019 that connects patients with in-network licensed therapists and psychiatrists through an online directory and matching platform. The company has raised over $65 million and has built insurance coverage across all 50 US states, making it one of the broadest-access in-network therapy platforms in the country. Rula handles provider credentialing, insurance contracting, billing, and claims processing on behalf of its network clinicians.\n\nRula's marketplace allows patients to search for therapists and psychiatrists by specialty, insurance, location, language, and availability, with real-time availability shown and direct booking enabled. The platform is designed to reduce the common friction points in finding in-network mental health care: lengthy wait times, confusing insurance directory inaccuracies, and billing surprises. Rula verifies insurance eligibility before the first appointment and provides upfront cost estimates so patients know their expected out-of-pocket responsibility.\n\nThe company has focused heavily on therapist experience and provider satisfaction, offering competitive reimbursement rates, automated billing, flexible scheduling, and dedicated support to attract and retain high-quality clinicians. Rula competes with Headway, Alma, and Grow Therapy in the therapist marketplace and infrastructure segment. With its 50-state insurance footprint and consumer-friendly search experience, Rula is positioned as an accessible alternative to the fragmented and often outdated directories maintained by health plans.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.